Clinical Implications of Circulating Tumor Cells in Advanced Colorectal Cancer

2012 ◽  
Vol 8 (4) ◽  
pp. 233-242
Author(s):  
Shahab Ahmed ◽  
Cathy Eng
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Advanced Colorectal Cancer ◽  
Clinical Implications

scholarly journals Circulating Tumor Cells in Gastrointestinal Malignancies: Current Techniques and Clinical Implications

2010 ◽  
Vol 2010 ◽  
pp. 1-9 ◽  
Author(s):  
Georg Lurje ◽  
Marc Schiesser ◽  
Andreas Claudius Hoffmann ◽  
Paul Magnus Schneider
Keyword(s):  
Colorectal Cancer ◽  
Clinical Outcome ◽  
Disease Progression ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Response To Therapy ◽  
Clinical Implications ◽  
Gastrointestinal Malignancies ◽  
Progression Of Disease

Since their introduction more than 50 years by Engell, circulating tumor cells (CTCs) have been evaluated in cancer patients and their detection has been correlated with clinical outcome, in esophageal, gastric, and colorectal cancer. With the availability of refined technologies, the identification of CTCs from peripheral blood is emerging as a useful tool for the detection of malignancy, monitoring disease progression, and measuring response to therapy. However, increasing evidence suggests a variety of factors to be responsible for disease progression. The analysis of a single CTC marker is therefore unlikely to accurately predict progression of disease with sufficient resolution and reproducibility. Here we discuss the current concept of CTCs, summarize the available techniques for their detection and characterization, and aim to provide a comprehensive update on the clinical implications of CTCs in gastrointestinal (GI) malignancies.

Biomarkers to predict the clinical efficacy of bevacizumab in advanced colorectal cancer: KRAS mutational status of circulating tumor cells.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e22030-e22030
Author(s):  
Marco Danova ◽  
Giuditta Comolli ◽  
Martina Torchio ◽  
Valerio Gristina ◽  
Alessandro Stefano Bertolini ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Clinical Efficacy ◽  
Advanced Colorectal Cancer ◽  
Mutational Status

Predictive value of circulating tumor cells positive for VEGFR expression in patients with advanced colorectal cancer undergoing treatment with FOLFOX plus bevacizumab.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e22026-e22026
Author(s):  
M. Jose Serrano ◽  
Francisco Gabriel Ortega ◽  
jose Antonio Lorente ◽  
Mayte Delgado ◽  
Jose Luis Puche
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Predictive Value ◽  
Advanced Colorectal Cancer

Genetic profiling of circulating tumor cells in patients with advanced colorectal cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e14113-e14113
Author(s):  
D. Ernst ◽  
I. Kubisch ◽  
A. de Albuquerque ◽  
S. Kaul ◽  
J. Boese-Landgraf ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Advanced Colorectal Cancer ◽  
Genetic Profiling

Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer

2020 ◽  
Vol 16 (18) ◽  
pp. 1289-1299
Author(s):  
Xiaohong Pan ◽  
Xiaoli Zhang
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Kras Mutation ◽  
Advanced Colorectal Cancer ◽  
Plasma Dna ◽  
Predictive Values ◽  
Early Risk ◽  
Colorectal Cancer Patients ◽  
Prognosis Indicator

Aim: Clinical management of colorectal cancer is challenging. Circulating tumor cells (CTCs) and DNA (ctDNA) are investigated to detect key KRAS mutation and for prognosis for risk stratifications. Materials & methods: 200 advance-stage patients with metastatic disease were selected and followed-up. Serial blood draws were used to quantify CTCs and ctDNA. Results: Both CTCs and ctDNA are strongly associated with colorectal cancer patients. The positive predictive values were 96.5 and 96.3% among CTCs and ctDNA, respectively, for all 200 patients using KRAS mutation. Specificity for healthy controls was 100%. As a prognosis indicator, results demonstrated that patients who had positive CTCs and plasma DNA had worse outcomes. Conclusion: Blood-based assessment of colorectal cancer shows promising results in early-risk stratifications.

Sign in / Sign up

Export Citation Format

Share Document